Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of KH815 injection in advanced solid tumors
CTR20251646Phase 2Active
- Sponsor
- Chengdu Kanghong Pharmaceutical Group
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of KH815 in Nonhematologic neoplasms, sponsored by Chengdu Kanghong Pharmaceutical Group. Started Jun 2025; status: active.
02
Drugs
KH815
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20251646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251646.